Clene FY2025 net loss narrows 34% to USD 26.17 million on revenue down 42% to USD 200,000

Reuters03-12

Clene FY2025 net loss narrows 34% to USD 26.17 million on revenue down 42% to USD 200,000

Clene reported a FY 2025 net loss of USD 26.17 million, narrowing 34% from the prior year. FY 2025 research and development expense fell 30% to USD 14.01 million, driven mainly by lower spending on the HEALEY ALS Platform Trial and RESCUE-ALS following completion of their blinded portions and open-label extensions. FY 2025 general and administrative expense decreased 31% to USD 9.23 million, reflecting lower insurance, legal, and public and investor relations costs. Cash and cash equivalents were USD 5.19 million at year-end, down 57%, and the company said its December 31, 2025 resources plus proceeds from a January 2026 registered direct offering are expected to fund operations to the end of Q3 2026. Rob Etherington said the next milestone is an in-person Type C FDA meeting expected by end of Q1 2026, with Clene planning to file an accelerated-approval NDA for CNM-Au8 in ALS by the end of June 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clene Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603120800PRIMZONEFULLFEED9670577) on March 12, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618913107?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-12 20:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618913107","market":"us","top_or_hot":-1,"title":"Clene FY2025 net loss narrows 34% to USD 26.17 million on revenue down 42% to USD 200,000","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Clene FY2025 net loss narrows 34% to USD 26.17 million on revenue down 42% to USD 200,000\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Clene reported a FY 2025 net loss of USD 26.17 million, narrowing 34% from the prior year. FY 2025 research and development expense fell 30% to USD 14.01 million, driven mainly by lower spending on the HEALEY ALS Platform Trial and RESCUE-ALS following completion of their blinded portions and open-label extensions. FY 2025 general and administrative expense decreased 31% to USD 9.23 million, reflecting lower insurance, legal, and public and investor relations costs. Cash and cash equivalents were USD 5.19 million at year-end, down 57%, and the company said its December 31, 2025 resources plus proceeds from a January 2026 registered direct offering are expected to fund operations to the end of Q3 2026. Rob Etherington said the next milestone is an in-person Type C FDA meeting expected by end of Q1 2026, with Clene planning to file an accelerated-approval NDA for CNM-Au8 in ALS by the end of June 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/CLNN\">Clene Inc</a>. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603120800PRIMZONEFULLFEED9670577) on March 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clene FY2025 net loss narrows 34% to USD 26.17 million on revenue down 42% to USD 200,000</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClene FY2025 net loss narrows 34% to USD 26.17 million on revenue down 42% to USD 200,000\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-12 20:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Clene FY2025 net loss narrows 34% to USD 26.17 million on revenue down 42% to USD 200,000\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Clene reported a FY 2025 net loss of USD 26.17 million, narrowing 34% from the prior year. FY 2025 research and development expense fell 30% to USD 14.01 million, driven mainly by lower spending on the HEALEY ALS Platform Trial and RESCUE-ALS following completion of their blinded portions and open-label extensions. FY 2025 general and administrative expense decreased 31% to USD 9.23 million, reflecting lower insurance, legal, and public and investor relations costs. Cash and cash equivalents were USD 5.19 million at year-end, down 57%, and the company said its December 31, 2025 resources plus proceeds from a January 2026 registered direct offering are expected to fund operations to the end of Q3 2026. Rob Etherington said the next milestone is an in-person Type C FDA meeting expected by end of Q1 2026, with Clene planning to file an accelerated-approval NDA for CNM-Au8 in ALS by the end of June 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/CLNN\">Clene Inc</a>. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603120800PRIMZONEFULLFEED9670577) on March 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nNDL7sNmvb:1","article_id":"2618913107","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618913107","pubTimestamp":1773317193,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Clene reported a FY 2025 net loss of USD 26.17 million, narrowing 34% from the prior year. FY 2025 research and development expense fell 30% to USD 14.01 million, driven mainly by lower spending on the HEALEY ALS Platform Trial and RESCUE-ALS following completion of their blinded portions and open-label extensions. FY 2025 general and administrative expense decreased 31% to USD 9.23 million, reflecting lower insurance, legal, and public and investor relations costs. Cash and cash equivalents were USD 5.19 million at year-end, down 57%, and the company said its December 31, 2025 resources plus proceeds from a January 2026 registered direct offering are expected to fund operations to the end of Q3 2026. Rob Etherington said the next milestone is an in-person Type C FDA meeting expected by end of Q1 2026, with Clene planning to file an accelerated-approval NDA for CNM-Au8 in ALS by the end of June 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4139":"生物科技","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","CLNN":"Clene Inc","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4112":"金融交易所和数据","BK4585":"ETF&股票定投概念","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","NDAQ":"纳斯达克OMX交易所"},"translate_title":"Clene 2025财年净亏损收窄34%至2617万美元，收入下降42%至20万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"CLNN":0.9},"content_text":"Clene FY2025 net loss narrows 34% to USD 26.17 million on revenue down 42% to USD 200,000\n    \n\n        Clene reported a FY 2025 net loss of USD 26.17 million, narrowing 34% from the prior year. FY 2025 research and development expense fell 30% to USD 14.01 million, driven mainly by lower spending on the HEALEY ALS Platform Trial and RESCUE-ALS following completion of their blinded portions and open-label extensions. FY 2025 general and administrative expense decreased 31% to USD 9.23 million, reflecting lower insurance, legal, and public and investor relations costs. Cash and cash equivalents were USD 5.19 million at year-end, down 57%, and the company said its December 31, 2025 resources plus proceeds from a January 2026 registered direct offering are expected to fund operations to the end of Q3 2026. Rob Etherington said the next milestone is an in-person Type C FDA meeting expected by end of Q1 2026, with Clene planning to file an accelerated-approval NDA for CNM-Au8 in ALS by the end of June 2026.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clene Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603120800PRIMZONEFULLFEED9670577) on March 12, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618913107","isCrawlerRequest":true}